AtriCure Reports Strong Growth and Innovations in Surgical Treatments for Atrial Fibrillation

### AtriCure's Strategic Growth in Surgical Treatments

AtriCure, Inc., a key player in surgical solutions for atrial fibrillation, reports promising financial results for the fourth quarter and full year of 2024. The company anticipates revenue of approximately $124.3 million for Q4, a notable 17% increase from the same quarter in 2023. This surge is largely driven by strong demand for AtriCure's innovative devices, including the cryoSPHERE® pain management devices, AtriClip® devices utilized in open-chest procedures, and the EnCompass® clamp. U.S. revenue is expected to reach $101.6 million, reflecting a robust 14% growth, while international sales are projected at $22.7 million, marking a significant 28% increase. These results underscore AtriCure's commitment to enhancing its product offerings and expanding its market presence.

In the broader context of its annual performance, AtriCure forecasts total revenue for 2024 at approximately $465.3 million, again reflecting a healthy 17% growth. The company also projects an adjusted EBITDA between $26 million and $29 million, alongside an adjusted loss per share ranging from $0.74 to $0.80. This performance illustrates AtriCure's resilience and adaptability in a competitive landscape, showcasing its focus on innovative solutions for managing atrial fibrillation and related conditions. The company’s growth trajectory is indicative of its strategic investments in product development and market penetration.

Looking ahead, AtriCure sets ambitious projections for 2025, anticipating revenue between $517 million and $527 million and an improved adjusted EBITDA of approximately $40 million to $44 million. President and CEO Michael Carrel expresses optimism about the company's momentum, highlighting ongoing efforts to drive innovation and growth, despite facing challenges in the U.S. Hybrid franchise. AtriCure plans to host an Analyst & Investor Day on March 26, 2025, in Mason, Ohio, aiming to showcase its product portfolio and outline future innovations, signaling a proactive approach to stakeholder engagement and market positioning.

### Other Relevant Insights

AtriCure’s focus on expanding its product offerings has positioned it favorably within the surgical treatment landscape for atrial fibrillation. The company’s successful introduction and performance of its cryoSPHERE® and AtriClip® devices reflect its commitment to addressing the needs of healthcare providers and patients alike.

As AtriCure prepares for its Analyst & Investor Day, the firm emphasizes its dedication to transparency and collaboration with stakeholders, which is essential for driving future growth and innovation in a rapidly evolving healthcare market.